Highlights

  • 4DMedical Ltd closed at AUD 4.64, down -1.70%, at the close of trading on 6 August 2026.
  • The S&P/ASX 200 Health Care (ASX: XHJ) Index closed at 28,235.50 points, up +0.81%, on 6 August 2026.
  • The broader S&P/ASX 200 (ASX: XJO) finished at 9,271.60 points, gaining +0.47% during the session.
  • 4DMedical Ltd is a medical technology company developing lung function imaging technology listed on the Australian Securities Exchange.

4DMedical Ltd (ASX:4DX) closed at AUD 4.64 at the close of trading on 6 August 2026, down -1.70% for the session. The broader S&P/ASX 200 Health Care (ASX: XHJ) Index advanced +0.81% to close at 28,235.50 points, while the S&P/ASX 200 (ASX: XJO) gained +0.47% to finish the day at 9,271.60 points.

Although the shares recorded a modest decline on the day, daily price movements should not automatically be interpreted as changes in the company's underlying business performance. Equity prices can fluctuate due to investor sentiment, sector-wide movements, macroeconomic developments and broader market conditions, even in the absence of company-specific developments.

Business Overview

4DMedical Ltd (ASX:4DX) is an Australian medical technology company that develops advanced lung function imaging technology using its proprietary XV Technology platform.

The company's technology enables three-dimensional, dynamic imaging of lung ventilation, allowing clinicians to assess regional airflow and identify patterns of lung disease that are not visible through conventional static imaging methods. 4DMedical's XV LVAS software has received regulatory clearance in the United States and Australia.

4DMedical is focused on establishing its technology within radiology departments, pulmonology practices and hospital systems, with revenue generated from software licences, image processing fees and services associated with its imaging platform.

Industry Position

Medical imaging technology continues to evolve, with innovations in software and hardware enabling clinicians to obtain increasingly detailed and functional assessments of patient physiology. Lung function imaging represents a specific area of unmet clinical need, given the limitations of conventional chest imaging in assessing regional airflow and dynamic lung behaviour.

4DMedical operates in an early-stage commercial environment, working to establish its XV Technology as a standard tool in the assessment of respiratory disease. The company's pathway to widespread adoption involves demonstrating clinical utility, securing reimbursement and building relationships with major imaging networks and hospital systems.

At the close of trading on 6 August 2026, the S&P/ASX 200 Health Care (ASX: XHJ) Index closed at 28,235.50 points, up +0.81%, while the broader S&P/ASX 200 (ASX: XJO) finished at 9,271.60 points, advancing +0.47% for the session.

What Investors Watch

For 4DMedical, investors typically monitor the pace of commercial adoption of the XV Technology platform, including the number of radiology sites operating the system and the volume of scans processed. Reimbursement progress in the United States, where CPT coding coverage can significantly influence clinical adoption, is a particularly important milestone.

The company's revenue trajectory, cash burn rate and funding position are also assessed, given that 4DMedical continues to invest in commercial and clinical activities ahead of reaching operational self-sufficiency. Clinical evidence development and publications supporting the clinical value of the technology are additional factors that can influence adoption and investor sentiment.

Understanding Share Price Movements

Daily share price movements in early-commercial medical technology companies can be influenced by changes in sentiment, trading volumes and broader market conditions that may not reflect changes in the company's operational trajectory.

For 4DMedical, the path from clinical validation to commercial scale involves multiple steps including site installations, reimbursement outcomes and clinical adoption, making the company's progress best assessed over longer timeframes rather than through short-term price movements.

Longer-term investors typically track 4DMedical's installed base growth, reimbursement milestones and revenue trajectory when assessing how the company is progressing towards commercial viability.

Long-Term Perspective

Medical imaging technology companies in early commercial stages often require extended periods to achieve widespread clinical adoption, as the integration of new technologies into established clinical pathways involves education, workflow adaptation and reimbursement pathway development.

For 4DMedical, long-term performance will be shaped by its ability to demonstrate clinical utility at scale, achieve broad reimbursement coverage and build commercial relationships with major radiology networks and hospital systems in its target markets.

The broader trend towards functional and dynamic imaging in respiratory medicine provides a supportive backdrop for companies seeking to introduce innovative lung assessment technologies into clinical practice.

Latest Developments

4DMedical continues developing its respiratory imaging technology platform, with ASX updates focused on commercial expansion, clinical adoption and healthcare partnerships. The company is working to increase utilisation of its XV Technology platform, targeting improved diagnosis and monitoring of respiratory diseases through advanced imaging solutions.

Final Takeaway

4DMedical's shares declined at the close on 6 August 2026, while the broader healthcare sector finished higher. The company continues to advance the commercial rollout of its XV Technology platform for lung function imaging in hospitals and radiology centres.

A daily share price decline does not necessarily indicate a change in the company's operational trajectory. Investors typically continue monitoring 4DMedical's site installations, reimbursement progress, scan volumes and cash management when assessing the company's development as a commercial medical technology business.

4DMedical shares closed at AUD 4.64, down 1.70% at the close of trading on 6 August 2026.

The S&P/ASX 200 Health Care (ASX: XHJ) Index closed at 28,235.50 points, up +0.81%, while the broader S&P/ASX 200 (ASX: XJO) finished at 9,271.60 points, advancing +0.47% on 6 August 2026.

4DMedical Ltd is an Australian medical technology company that develops advanced lung function imaging technology using its proprietary XV Technology platform.

No. Daily share price movements can reflect broader market sentiment, sector performance and investor positioning and do not necessarily indicate changes in a company's underlying business performance.